Neon Therapeutics Enters License Agreement with Broad Institute, Dana-Farber and Mass General

Neon Therapeutics Enters License Agreement with Broad Institute, Dana-Farber and Mass General

Firm News

Related Solutions

Providing comprehensive solutions for the acquisition, enforcement and protection of IP.
A global team handling highly complex and sensitive matters in all aspects of litigation.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On December 9, 2015, Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, announced that the company has entered into a license agreement with the Broad Institute, Dana-Farber Cancer Institute and Massachusetts General Hospital for technology to be utilized in Neon Therapeutics' pipeline.

Neon Therapeutics was represented by WilmerHale in this transaction, with Partners Richard Hoffman and Michael Bevilacqua, and Associate Ritu Gupta.

View Neon Therapeutics' press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel